Remus Pharmaceuticals appoints Tapan Shah as Secretarial Auditor
Remus Pharmaceuticals Limited appointed Mr. Tapan Shah as Secretarial Auditor for FY 2026-2027 on May 20, 2026. The Board approved the appointment based on the Audit Committee's recommendation. Mr. Shah brings over two decades of experience in corporate and regulatory compliance.
*this image is generated using AI for illustrative purposes only.
Remus Pharmaceuticals Limited has appointed Mr. Tapan Shah as its Secretarial Auditor for the financial year 2026-2027. The decision was taken by the Board of Directors during a meeting held on May 20, 2026, based on the recommendation of the Audit Committee.
Appointment Details
The appointment of Mr. Tapan Shah, a Practicing Company Secretary, was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. He has been assigned the task of conducting the Secretarial Audit for the company for the specified financial year.
Auditor Profile
Mr. Tapan Shah holds a Certificate of Practice No. 2839 and Membership No. FCS 4476. He is a peer-reviewed practicing Company Secretary with over 25 years of experience. His professional background includes providing services to listed companies, SMEs, multinational corporations, Section 8 entities, and LLPs. His expertise covers corporate laws, SEBI laws, stock exchange matters, and various regulatory compliance services.
The company confirmed that there are no relationships between Mr. Tapan Shah and the directors of the company that require disclosure under the relevant regulations. The appointment is effective from May 20, 2026.
| Particulars | Details |
|---|---|
| Name of the Secretarial Auditor | Mr. Tapan Shah, Practicing Company Secretary |
| Reason for change | Appointment |
| Date of appointment | May 20, 2026 |
| Term of appointment | FY 2026-2027 |
| Disclosure of relationships | Not Applicable |
Historical Stock Returns for Remus Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -5.88% | +11.46% | +23.80% | +10.69% | -61.17% | -66.01% |
What were the findings of the previous secretarial audit, and could any identified compliance gaps influence Remus Pharmaceuticals' regulatory strategy for FY 2026-2027?
How might Mr. Tapan Shah's extensive experience with SEBI regulations impact Remus Pharmaceuticals' approach to upcoming corporate governance disclosures or potential capital market activities?
Is Remus Pharmaceuticals planning any significant corporate actions—such as mergers, acquisitions, or fundraising—in FY 2026-2027 that could make this secretarial audit particularly consequential?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
